There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Viking Therapeutics (VKTX – Research Report) and ...

Fintel reports that on April 24, 2025, Maxim Group initiated coverage of Castellum (NYSEAM:CTM) with a Buy recommendation.

Maxim Group analyst Michael Okunewitch maintained a Buy rating on Rezolute (RZLT – Research Report) yesterday and set a price target of $15.00.

Columbia Threadneedle Investments has welcomed Francesca Mace Wilson to the EMEA equity trading desk, following more than five years at Capital Group, The TRADE can reveal. The move sees her leaving ...

The standing of UnitedHealth Group among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations ...

The standing of Lucid Group among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations ...

Deciphering Analyst Ratings: An In-Depth Analysis The standing of Cava Group among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below ...

Robert Isom; President, Chief Executive Officer, Director; American Airlines Group Inc Devon May ... we will open the call for analyst questions, followed by questions from the media.

Mizuho upped their price target on shares of UnitedHealth Group from $600.00 to $650.00 and gave the stock an “outperform” rating in a report on Wednesday, April 9th. One research analyst has ...

Analysts from Maxim Group have noted that Checha’s revenue and bottom-line results exceeded projections, while their outlook remains positive. Additionally, the company plans to leverage AI and ...

On December 16, 2024, Maxim Group started coverage of CMCL with a Buy rating and a price target of $17. According to the investment firm, the company is on the path to solid growth, with gold ...

On Thursday, H.C. Wainwright analyst Joseph Pantginis reaffirmed a Buy rating and a $37.00 price target for Pharming Group (NASDAQ: PHAR), representing significant upside potential from current ...